Drug Trial Radar · NCT07242638
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Jan 12, 2026
Primary completion
Feb 23, 2029
Study completion Feb 23, 2029
Sponsor
- Lead sponsor
- Icahn School of Medicine at Mount SinaiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Columbia University; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- First posted
- Nov 21, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) 75 response for AD, or SALT \<= 20 for AA) will be kept on this dose, and non-responders based on these definitions, will initiate 200 mg daily for another 12 weeks. All AD and AA patients will be maintained on the respective dose of Abrocitinib from Week 24 through week 60.
Conditions
- Atopic Dermatitis
- Alopecia Areata
Interventions
AbrocitinibDrug
All participants will be started on 100mg Abrocitinib daily. Based on clinical response, non-responders will be increased to 200mg daily at week 12. Responders will continue to receive 100 mg dose of Abrocitinib. All AA and AD participants will be maintained on their dose of Abrocitinib through week 60.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Serious Adverse Events (SAEs) at Week 24 and Week 60Time frame: Week 24 and Week 60
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.